HIM
KNSA icon

Hillsdale Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Hillsdale Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-224,074
Closed -$9.24M – 722
2025
Q4 		$9.24M Sell
224,074
-1,300
-0.6% -$52.1K 0.26% 67
2025
Q3 		$8.75M Buy
225,374
+24,800
+12% +$806K 0.26% 64
2025
Q2 		$5.55M Buy
+200,574
New +$5.11M 0.2% 132
2023
Q1 		– Sell
-244,017
Closed -$3.66M – 612
2022
Q4 		$3.66M Buy
+244,017
New +$3.55M 0.31% 123

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Hillsdale Investment Management's KNSA Position: Q1 2026 in Review

Hillsdale Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 224,074 shares — an estimated $9.24M sold.

Hillsdale Investment Management first reported a position in KNSA in Q4 2022 and held it in 4 quarters. The position peaked at $9.24M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Hillsdale Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 224,074 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $9.24M.
  • Hillsdale Investment Management first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Hillsdale Investment Management's Kiniksa Pharmaceuticals position peaked at $9.24M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.